Disease-Modifying Antirheumatic Drugs in Children With Juvenile Idiopathic Arthritis
Conclusions About Benefits and Adverse Effects of DMARDs (2 of 2)
Few studies of sufficient size make direct comparisons of DMARDs in well-characterized patient populations; thus, it is not clear in which circumstances one DMARD will yield better outcomes than another.
No one instrument for measuring disease activity or functional status has been identified as clearly superior.
Evidence about the rate, types, and severity of adverse effects is too limited to permit conclusions about risks.
Keywords: juvenile idiopathic arthritis | JIA | JRA | juvenile rheumatoid arthritis | JCA | DMARDs | disease-modifying | antirheumatic | anti-rheumatic | rheumatic | TNF-alpha blockers | biologic DMARD | nonbiologic DMARD | non-biologic DMARD
- Kemper A, Coeytaux R, Sanders G, et al. Disease-Modifying Antirheumatic Drugs (DMARDs) in Children With Juvenile Idiopathic Arthritis (JIA). Comparative Effectiveness Review No. 28 (Prepared by the Duke Evidence-based Practice Center under Contract No. HHSA 290-2007-10066-I). Rockville, MD: Agency for Healthcare Research and Quality; September 2011. AHRQ Publication No. 11-EHC039-EF. Available at www.effectivehealthcare.ahrq.gov/dmardsjia.cfm.
Your slide tray is being processed.